Therapy Areas
Innovent Biologics doses first patient in taletrectinib Phase II basket trial
18 June 2021 -

Innovent Biologics Inc (HKEX: 01801), a biopharmaceutical company that develops, manufactures and commercialises high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced on Thursday that it has dosed its first patient in a Phase II basket trial of taletrectinib for solid tumours containing NTRK fusion (NCT04617054).

The company signed an exclusive agreement with AnHeart Therapeutics Co. Ltd. on June 2021. Under the contract, Innovent Biologics Inc received rights to co-develop and commercialise taletrectinib in Greater China.

The product is an investigational next-generation tyrosine kinase inhibitor aimed at effectively targeting ROS1 and NTRK fusion mutations with potential to treat TKI-naive or pre-treated patients.